This company has been marked as potentially delisted and may not be actively trading. Flex Pharma (FLKS) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrendsBuy This Stock FLKS vs. EGRX, NLTX, NNVC, HILS, IBIO, TAOX, AEON, OBSV, AEZS, and SPRBShould you be buying Flex Pharma stock or one of its competitors? The main competitors of Flex Pharma include Eagle Pharmaceuticals (EGRX), Neoleukin Therapeutics (NLTX), NanoViricides (NNVC), Hillstream BioPharma (HILS), iBio (IBIO), Synaptogenix (TAOX), AEON Biopharma (AEON), ObsEva (OBSV), Aeterna Zentaris (AEZS), and Spruce Biosciences (SPRB). Flex Pharma vs. Its Competitors Eagle Pharmaceuticals Neoleukin Therapeutics NanoViricides Hillstream BioPharma iBio Synaptogenix AEON Biopharma ObsEva Aeterna Zentaris Spruce Biosciences Flex Pharma (NASDAQ:FLKS) and Eagle Pharmaceuticals (NASDAQ:EGRX) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, profitability, earnings, analyst recommendations, media sentiment, institutional ownership, dividends and valuation. Is FLKS or EGRX more profitable? Eagle Pharmaceuticals has a net margin of 0.00% compared to Flex Pharma's net margin of -1,208.42%. Eagle Pharmaceuticals' return on equity of 0.00% beat Flex Pharma's return on equity.Company Net Margins Return on Equity Return on Assets Flex Pharma-1,208.42% -98.04% -83.37% Eagle Pharmaceuticals N/A N/A N/A Which has better valuation & earnings, FLKS or EGRX? Eagle Pharmaceuticals has higher revenue and earnings than Flex Pharma. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioFlex Pharma$840K9.93-$21.92MN/AN/AEagle Pharmaceuticals$257.55M0.16$35.64MN/AN/A Which has more volatility & risk, FLKS or EGRX? Flex Pharma has a beta of 1.65, indicating that its stock price is 65% more volatile than the S&P 500. Comparatively, Eagle Pharmaceuticals has a beta of 0.83, indicating that its stock price is 17% less volatile than the S&P 500. Do insiders and institutionals hold more shares of FLKS or EGRX? 14.4% of Flex Pharma shares are held by institutional investors. Comparatively, 85.4% of Eagle Pharmaceuticals shares are held by institutional investors. 7.6% of Flex Pharma shares are held by insiders. Comparatively, 28.9% of Eagle Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Does the media prefer FLKS or EGRX? In the previous week, Flex Pharma's average media sentiment score of 0.00 equaled Eagle Pharmaceuticals'average media sentiment score. Company Overall Sentiment Flex Pharma Neutral Eagle Pharmaceuticals Neutral SummaryEagle Pharmaceuticals beats Flex Pharma on 7 of the 9 factors compared between the two stocks. Get Flex Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for FLKS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding FLKS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart FLKS vs. The Competition Export to ExcelMetricFlex PharmaPharmaceutical Preparations IndustryMedical SectorNASDAQ ExchangeMarket Cap$8.35M$852.33M$5.67B$9.83BDividend YieldN/A4.84%3.79%4.08%P/E RatioN/A1.1930.5825.12Price / Sales9.9326.45463.49115.90Price / CashN/A19.5637.4059.05Price / Book0.916.589.096.18Net Income-$21.92M-$4.98M$3.25B$264.89M Flex Pharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)FLKSFlex PharmaN/A$0.46+2.0%N/A-76.9%$8.35M$840K0.004Gap DownEGRXEagle PharmaceuticalsN/A$3.19flatN/AN/A$41.43M$257.55M0.00100NLTXNeoleukin TherapeuticsN/A$21.72-0.3%N/A-39.8%$32.80MN/A-6.9890News CoverageGap DownNNVCNanoViricides0.313 of 5 stars$1.58-0.6%N/A-21.9%$25.39MN/A-2.1920HILSHillstream BioPharmaN/A$1.24-0.4%N/A-54.5%$21.83MN/A-1.721IBIOiBio1.187 of 5 stars$0.62-1.6%$5.00+702.7%-59.9%$10.29M$375K0.00100TAOXSynaptogenixN/A$5.89-9.2%N/AN/A$9.02MN/A-0.584Positive NewsEarnings ReportAEONAEON Biopharma3.4462 of 5 stars$0.73+1.6%$360.00+48,919.6%-99.0%$8.30MN/A4.085Gap UpOBSVObsEvaN/AN/AN/AN/A$7.94MN/A0.0050AEZSAeterna ZentarisN/A$3.82-2.1%N/A-46.2%$6.85M$2.37M-0.2620SPRBSpruce Biosciences2.0491 of 5 stars$0.14+12.5%$131.25+97,122.2%-73.5%$5.70M$4.91M-0.1420News CoverageShort Interest ↑Gap Down Related Companies and Tools Related Companies Eagle Pharmaceuticals Competitors Neoleukin Therapeutics Competitors NanoViricides Competitors Hillstream BioPharma Competitors iBio Competitors Synaptogenix Competitors AEON Biopharma Competitors ObsEva Competitors Aeterna Zentaris Competitors Spruce Biosciences Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:FLKS) was last updated on 8/16/2025 by MarketBeat.com Staff From Our PartnersMusk’s Project Colossus could mint millionairesI predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | SponsoredGenesis 14:13-17 [HIDDEN MEANING?]A mysterious Bible verse from Genesis may hold the key to unlocking what one expert calls an “American birthri...Paradigm Press | SponsoredTrump's New Plan to “Make China Pay”Trump's AI Masterplan Could Crush China The White House just unleashed would could be the most aggressive e...Stansberry Research | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredIs This Stock the 'Next Nvidia'?'AI Bottleneck' Now Threatens Entire Magnificent 7 A new critical failure has appeared in the AI market, an...Altimetry | SponsoredWhen the levee breaksThe U.S. Treasury just confirmed it plans to borrow $1.01 trillion this quarter—nearly double what was project...Porter & Company | SponsoredBut this $20 American company could control the secretThe "Impossible" Chip That Runs on Pure Light Google's quantum computer shocked the world... but China DEMO...The Oxford Club | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Flex Pharma Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Flex Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access